{"id":1013,"date":"2014-07-01T00:33:42","date_gmt":"2014-07-01T00:33:42","guid":{"rendered":"http:\/\/phosdev.com\/todaysveterinarypractice\/?p=1013"},"modified":"2022-02-16T15:55:14","modified_gmt":"2022-02-16T15:55:14","slug":"diagnosis-treatment-of-keratoconjunctivitis-sicca-in-dogs","status":"publish","type":"post","link":"https:\/\/navc.sitepreview.app\/todaysveterinarypractice.com\/ophthalmology\/diagnosis-treatment-of-keratoconjunctivitis-sicca-in-dogs\/","title":{"rendered":"Diagnosis &amp; Treatment of Keratoconjunctivitis Sicca in Dogs"},"content":{"rendered":"<p><a href=\"https:\/\/todaysveterinarypractice.com\/wp-content\/uploads\/sites\/4\/2016\/06\/T1407F01.pdf\"><img decoding=\"async\" class=\"alignnone size-full wp-image-9886\" src=\"https:\/\/todaysveterinarypractice.com\/wp-content\/uploads\/sites\/4\/2011\/07\/pdf_button.png\" alt=\"pdf_button\" width=\"110\" height=\"27\" \/><\/a><\/p>\n<hr \/>\n<p><em>Lori J. Best, DVM; Diane V.H. Hendrix, DVM, Diplomate ACVO; and Daniel A. Ward, DVM, PhD, Diplomate ACVO<\/em><\/p>\n<p>Keratoconjunctivitis sicca (KCS), is a relatively common condition in dogs, although the diagnosis is often overlooked. This article provides guidance on the pathophysiology, causes, diagnosis, and medical and surgical treatment for this condition.<\/p>\n<hr \/>\n<p class=\"drop-cap\"><span class=\"helvmeditalic-9-5\">K<\/span><span class=\"garamond-9-5\">eratoconjunctivitis sicca (KCS) is a relatively common condition in dogs. Although KCS can be diagnosed readily with a thorough ophthalmic examination, the diagnosis is often overlooked.<\/span><\/p>\n<p class=\"indent-125\"><span class=\"garamond-9-5\">KCS is an inflammatory condition of the cornea and conjunctiva, secondary to a deficiency of the precorneal tear film (PTF). KCS is categorized by tear film deficiency:<\/span><\/p>\n<p class=\"tabs-and-bullets\"><span class=\"helvbold-9-5\">\u2022 <\/span><span class=\"garamond-bold\">Quantitative KCS<\/span><span class=\"garamond-9-5\"> is a decrease in the <\/span><span class=\"garamon-italics\">aqueous component<\/span><span class=\"garamond-9-5\"> of the tear film as measured with the Schirmer tear test (STT); it is recognized more commonly in veterinary medicine.<\/span><\/p>\n<p class=\"tabs-and-bullets\"><span class=\"helvbold-9-5\">\u2022 <\/span><span class=\"garamond-bold\">Qualitative KCS<\/span><span class=\"garamond-9-5\"> is a decrease in the <\/span><span class=\"garamon-italics\">lipid or mucin components<\/span><span class=\"garamond-9-5\"> of the tear film and diagnosed by documenting decreased tear film breakup time (TBUT).<\/span><\/p>\n<table border=\"0\" width=\"100%\" cellspacing=\"1\" cellpadding=\"10\">\n<tbody>\n<tr>\n<td bgcolor=\"#e9f4f8\">\n<h3><strong><span class=\"aquabold\">The Lacrimal System &amp; Tear Film<\/span><\/strong><\/h3>\n<p>Normal PTF is estimated to be anywhere from 3 to 45 microns thick in humans and, in most species, is composed of aqueous, lipid, and mucin layers, which were once thought to be present in a laminar arrangement (<strong>Table 1<\/strong>).<sup>1,2<\/sup> More recent evidence suggests that PTF may resemble a muco-aqueous pool covered in a very thin lipid layer rather than a trilaminar structure.<sup>3<\/sup><\/p>\n<table border=\"0\" width=\"100%\" cellspacing=\"2\" cellpadding=\"3\">\n<tbody>\n<tr>\n<td class=\"bluboldheader\" colspan=\"5\" align=\"center\" bgcolor=\"#ffffff\">Table 1. Structure of Precorneal Tear Film<\/td>\n<\/tr>\n<tr>\n<td bgcolor=\"#ffffff\"><\/td>\n<td class=\"purple\" bgcolor=\"#ffffff\">AREA OF PRODUCTION<\/td>\n<td class=\"purple\" bgcolor=\"#ffffff\">FUNCTION<\/td>\n<td class=\"purple\" bgcolor=\"#ffffff\">TYPE OF DEFICIENCY<\/td>\n<td class=\"purple\" bgcolor=\"#ffffff\">DIAGNOSTIC TEST<\/td>\n<\/tr>\n<tr>\n<td class=\"blue\" valign=\"top\" bgcolor=\"#d8efe1\">LIPID<\/td>\n<td valign=\"top\" bgcolor=\"#c2e9d1\">Meibomian glands<\/td>\n<td valign=\"top\" bgcolor=\"#d8efe1\">\u2022 Limits evaporation<br \/>\n\u2022 Binds tear film to cornea<br \/>\n\u2022 Provides surface tension to prevent tear film overflow<\/td>\n<td valign=\"top\" bgcolor=\"#c2e9d1\">Qualitative<\/td>\n<td valign=\"top\" bgcolor=\"#d8efe1\">Decrease in TBUT<\/td>\n<\/tr>\n<tr>\n<td class=\"blue\" valign=\"top\" bgcolor=\"#d8efe1\">AQUEOUS<\/td>\n<td valign=\"top\" bgcolor=\"#c2e9d1\">Orbital and nictitans lacrimal glands<\/td>\n<td valign=\"top\" bgcolor=\"#d8efe1\">\u2022 Provides corneal nutrition, surface lubrication, and smooth surface for optical clarity<br \/>\n\u2022 Removes waste material and bacteria<\/td>\n<td valign=\"top\" bgcolor=\"#c2e9d1\">Quantitative<\/td>\n<td valign=\"top\" bgcolor=\"#d8efe1\">Decrease in STT value<\/td>\n<\/tr>\n<tr>\n<td class=\"blue\" valign=\"top\" bgcolor=\"#d8efe1\">MUCIN<\/td>\n<td valign=\"top\" bgcolor=\"#c2e9d1\">Conjunctival goblet cells<\/td>\n<td valign=\"top\" bgcolor=\"#d8efe1\">\u2022 Enhances spread of tear film<\/td>\n<td valign=\"top\" bgcolor=\"#c2e9d1\">Qualitative<\/td>\n<td valign=\"top\" bgcolor=\"#d8efe1\">Decrease in TBUT<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Lacrimal secretion is stimulated via sensory input from the cornea, periocular structures, and globe. The ophthalmic and maxillary divisions of the trigeminal nerve serve as the afferent part of the reflex arc; then motor input travels to the lacrimal glands via the parasympathetic division of the facial nerve as the efferent arc. Tears are then secreted following contraction of lacrimal acinar myoepithelium.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2 class=\"indent-125\"><strong><span class=\"bluboldheader\">PATHOPHYSIOLOGY<\/span><\/strong><\/h2>\n<p class=\"indent-125\"><span class=\"garamond-9-5\">Tear film deficiencies lead to:<\/span><\/p>\n<p class=\"tabs-and-bullets\"><span class=\"helvbold-9-5\">\u2022 <\/span><span class=\"garamond-9-5\">Chronic inflammation of the ocular surface secondary to increased surface friction<\/span><\/p>\n<p class=\"tabs-and-bullets\"><span class=\"helvbold-9-5\">\u2022 <\/span><span class=\"garamond-9-5\">Secondary infection<\/span><\/p>\n<p class=\"tabs-and-bullets\"><span class=\"helvbold-9-5\">\u2022 <\/span><span class=\"garamond-9-5\">Dehydration and malnutrition of the corneal and conjunctival epithelium.<\/span><\/p>\n<p class=\"tabs-and-bullets\"><span class=\"garamond-9-5\">This latter combination makes ulcerations more prone to infection, possibly resulting in keratomalacia and perforation.<\/span><\/p>\n<p class=\"indent-125\"><span class=\"garamond-9-5\">Chronic surface irritation results in:<\/span><\/p>\n<p class=\"tabs-and-bullets\"><span class=\"helvbold-9-5\">\u2022 <\/span><span class=\"garamond-9-5\">Conjunctival hyperemia<\/span><\/p>\n<p class=\"tabs-and-bullets\"><span class=\"helvbold-9-5\">\u2022 <\/span><span class=\"garamond-9-5\">Squamous metaplasia of the surface epithelium<\/span><\/p>\n<p class=\"tabs-and-bullets\"><span class=\"helvbold-9-5\">\u2022 <\/span><span class=\"garamond-9-5\">Hyperkeratinization of the surface epithelium<\/span><\/p>\n<p class=\"tabs-and-bullets\"><span class=\"helvbold-9-5\">\u2022 <\/span><span class=\"garamond-9-5\">Thickening of the corneal epithelium.<\/span><\/p>\n<p class=\"indent-125\"><span class=\"garamond-9-5\">Inflammatory cells and blood vessels enter the anterior corneal stroma, depositing pigment, lipids, and calcium. The vascularization and deposits stabilize the cornea and make it less susceptible to ulceration; however, their presence can result in vision loss.<\/span><\/p>\n<h2 class=\"indent-125\"><strong><span class=\"bluboldheader\">QUANTITATIVE KCS<\/span><\/strong><\/h2>\n<h3 class=\"indent-125\"><\/h3>\n<h3 class=\"indent-125\"><strong><span class=\"font_purple\">Causes<\/span><\/strong><\/h3>\n<p class=\"no-indent-\"><span class=\"garamond-9-5\">Causes of quantitative KCS\u2014organized by type of cause\u2014are listed in <\/span><strong><span class=\"garamond-bold\">Table 2<\/span><\/strong><span class=\"garamond-9-5\">. The most common cause is immune-mediated lacrimal adenitis. Transient decreases in tear production can be iatrogenically caused by:<\/span><\/p>\n<p class=\"tabs-and-bullets\"><span class=\"helvbold-9-5\">\u2022 <\/span><span class=\"garamond-9-5\">General anesthesia: Significantly decreases tear production for up to 24 H4<\/span><\/p>\n<p class=\"tabs-and-bullets\"><span class=\"helvbold-9-5\">\u2022 <\/span><span class=\"garamond-9-5\">Xylazine, medetomidine, and butorphanol: Significantly decrease tear production temporarily<sup>5,6<\/sup><\/span><\/p>\n<p class=\"tabs-and-bullets\"><span class=\"helvbold-9-5\">\u2022 <\/span><span class=\"garamond-9-5\">Topical or systemic atropine: Causes secondary decrease in tear production that is not clinically significant in most dogs.<\/span><\/p>\n<p class=\"indent-125\"><span class=\"garamond-9-5\">Therefore, artificial tear ointments are important adjuncts to sedation and anesthesia regimens, and should be continued until dogs are fully responsive and consistently blinking appropriately.<\/span><\/p>\n<table border=\"0\" width=\"100%\" cellspacing=\"2\" cellpadding=\"3\">\n<tbody>\n<tr>\n<td class=\"bluboldheader\" colspan=\"5\" align=\"center\" bgcolor=\"#ffffff\">Table 2. Causes of Quantitative KCS<\/td>\n<\/tr>\n<tr>\n<td bgcolor=\"#ffffff\"><span class=\"purple\">CAUSE<\/span><\/td>\n<td class=\"purple\" bgcolor=\"#ffffff\">PATHOGENESIS<\/td>\n<td class=\"purple\" bgcolor=\"#ffffff\">PREDISPOSITION<\/td>\n<td class=\"purple\" bgcolor=\"#ffffff\">DURATION<\/td>\n<td class=\"purple\" bgcolor=\"#ffffff\">PROGNOSISa<\/td>\n<\/tr>\n<tr>\n<td class=\"blue\" colspan=\"5\" valign=\"top\" bgcolor=\"#d8efe1\">Disease (Ophthalmic)<\/td>\n<\/tr>\n<tr>\n<td class=\"blue\" valign=\"top\" bgcolor=\"#d8efe1\"><span class=\"purple\">Chronic severe conjunctivitis<\/span><\/td>\n<td valign=\"top\" bgcolor=\"#c2e9d1\">Swelling of excretory ductules of lacrimal gland<\/td>\n<td valign=\"top\" bgcolor=\"#d8efe1\">None<\/td>\n<td valign=\"top\" bgcolor=\"#c2e9d1\">Variable: Permanent if scarring present<\/td>\n<td valign=\"top\" bgcolor=\"#d8efe1\">Good<\/td>\n<\/tr>\n<tr>\n<td class=\"blue\" valign=\"top\" bgcolor=\"#d8efe1\"><span class=\"purple\">Immune-mediated lacrimal adenitis (primary KCS)<\/span><\/td>\n<td valign=\"top\" bgcolor=\"#c2e9d1\">Immune-mediated destruction of lacrimal tissue with secondary atrophy<sup>7<\/sup><\/td>\n<td valign=\"top\" bgcolor=\"#d8efe1\">Most common cause of canine KCSb<\/td>\n<td valign=\"top\" bgcolor=\"#c2e9d1\">Lifelong<\/td>\n<td valign=\"top\" bgcolor=\"#d8efe1\">Good<\/td>\n<\/tr>\n<tr>\n<td class=\"blue\" colspan=\"5\" valign=\"top\" bgcolor=\"#d8efe1\">Disease (Other)<\/td>\n<\/tr>\n<tr>\n<td class=\"purple\" valign=\"top\" bgcolor=\"#d8efe1\">Canine distemper virus<sup>8<\/sup><\/td>\n<td valign=\"top\" bgcolor=\"#c2e9d1\">Lacrimal adenitis<\/td>\n<td valign=\"top\" bgcolor=\"#d8efe1\">Unvaccinated animals<\/td>\n<td valign=\"top\" bgcolor=\"#c2e9d1\">Variable: Many spontaneously recover<\/td>\n<td valign=\"top\" bgcolor=\"#d8efe1\">Good to fair: If systemic disease survived, many recover<\/td>\n<\/tr>\n<tr>\n<td class=\"purple\" valign=\"top\" bgcolor=\"#d8efe1\">Idiopathic neurogenic<sup>9<\/sup><\/td>\n<td valign=\"top\" bgcolor=\"#c2e9d1\">Idiopathic: Present with ipsilateral dry nose<\/td>\n<td valign=\"top\" bgcolor=\"#d8efe1\">Middle-aged female dogs<\/td>\n<td valign=\"top\" bgcolor=\"#c2e9d1\">Variable<\/td>\n<td valign=\"top\" bgcolor=\"#d8efe1\">Good to fair: Some spontaneously resolve<\/td>\n<\/tr>\n<tr>\n<td class=\"purple\" valign=\"top\" bgcolor=\"#d8efe1\">Leishmaniasis<sup>10<\/sup><\/td>\n<td valign=\"top\" bgcolor=\"#c2e9d1\">Lacrimal adenitis, especially surrounding lacrimal gland ducts, where amastigotes accumulate<\/td>\n<td valign=\"top\" bgcolor=\"#d8efe1\">Animals in Mediterranean region or with travel history<\/td>\n<td valign=\"top\" bgcolor=\"#c2e9d1\">Variable<\/td>\n<td valign=\"top\" bgcolor=\"#d8efe1\">Fair<\/td>\n<\/tr>\n<tr>\n<td class=\"blue\" colspan=\"5\" valign=\"top\" bgcolor=\"#d8efe1\">Hereditary<\/td>\n<\/tr>\n<tr>\n<td class=\"purple\" valign=\"top\" bgcolor=\"#d8efe1\">Congenital alacrima<\/td>\n<td valign=\"top\" bgcolor=\"#c2e9d1\">Developmental absence of lacrimal tissue<\/td>\n<td valign=\"top\" bgcolor=\"#d8efe1\">Yorkshire terrier overrepresented<sup>11<\/sup><\/td>\n<td valign=\"top\" bgcolor=\"#c2e9d1\">Permanent; present at birth<\/td>\n<td valign=\"top\" bgcolor=\"#d8efe1\">Poor: Often requires surgery<\/td>\n<\/tr>\n<tr>\n<td class=\"blue\" colspan=\"5\" valign=\"top\" bgcolor=\"#d8efe1\">Medication<\/td>\n<\/tr>\n<tr>\n<td class=\"purple\" valign=\"top\" bgcolor=\"#d8efe1\">Etodolac<sup>12<\/sup><\/td>\n<td valign=\"top\" bgcolor=\"#c2e9d1\">Nitrogen-containing pyrimidine\/pyridine rings have direct toxic effect on lacrimal acinar cells<\/td>\n<td valign=\"top\" bgcolor=\"#d8efe1\">None<\/td>\n<td valign=\"top\" bgcolor=\"#c2e9d1\">Variable<\/td>\n<td valign=\"top\" bgcolor=\"#d8efe1\">Fair: If etodolac administration &lt; 6 months, more likely to recover<\/td>\n<\/tr>\n<tr>\n<td class=\"purple\" valign=\"top\" bgcolor=\"#d8efe1\">Sulfa-derivative medications<sup>13<\/sup> &amp; related compounds<sup>14<\/sup><\/td>\n<td valign=\"top\" bgcolor=\"#c2e9d1\">Nitrogen-containing pyrimidine\/pyridine rings have direct toxic effect on lacrimal acinar cells<\/td>\n<td valign=\"top\" bgcolor=\"#d8efe1\">Typical onset within 30 days of medication initiation<sup>5<\/sup><\/td>\n<td valign=\"top\" bgcolor=\"#c2e9d1\">Variable: May resolve in 45\u201360 days or sometimes lifelong<\/td>\n<td valign=\"top\" bgcolor=\"#d8efe1\">Fair: Discontinue medication immediately after decrease in STT<\/td>\n<\/tr>\n<tr>\n<td class=\"blue\" colspan=\"5\" valign=\"top\" bgcolor=\"#d8efe1\">Treatment\/Trauma<\/td>\n<\/tr>\n<tr>\n<td class=\"purple\" valign=\"top\" bgcolor=\"#d8efe1\">Iatrogenic: Removal of third eyelid gland<\/td>\n<td valign=\"top\" bgcolor=\"#c2e9d1\">May decrease tear production and TBUT<sup>15<\/sup><\/td>\n<td valign=\"top\" bgcolor=\"#d8efe1\">None: History of removal of gland<\/td>\n<td valign=\"top\" bgcolor=\"#c2e9d1\">Variable<\/td>\n<td valign=\"top\" bgcolor=\"#d8efe1\">Fair<\/td>\n<\/tr>\n<tr>\n<td class=\"purple\" valign=\"top\" bgcolor=\"#d8efe1\">Local radiation therapy<sup>16<\/sup><\/td>\n<td valign=\"top\" bgcolor=\"#c2e9d1\">Acute adverse effect of radiation exposure<\/td>\n<td valign=\"top\" bgcolor=\"#d8efe1\">None<\/td>\n<td valign=\"top\" bgcolor=\"#c2e9d1\">Variable: Dose dependent and patient sensitivity<\/td>\n<td valign=\"top\" bgcolor=\"#d8efe1\">Fair<\/td>\n<\/tr>\n<tr>\n<td class=\"purple\" valign=\"top\" bgcolor=\"#d8efe1\">Trauma to lacrimal gland or nerves<sup>9<\/sup><\/td>\n<td valign=\"top\" bgcolor=\"#c2e9d1\">Decreased production\/ distribution of PTF due to decreased blinking and\/or increased evaporation secondary to lagophthalmia<sup>17<\/sup><\/td>\n<td valign=\"top\" bgcolor=\"#d8efe1\">None<\/td>\n<td valign=\"top\" bgcolor=\"#c2e9d1\">Variable<\/td>\n<td valign=\"top\" bgcolor=\"#d8efe1\">Fair to poor<\/td>\n<\/tr>\n<tr>\n<td class=\"italic\" colspan=\"5\" valign=\"top\" bgcolor=\"#ffffff\">a. Based on initiation of medical management<br \/>\nb. Many breeds are predisposed to primary KCS, including, but not limited to, the American cocker spaniel, cavalier King Charles spaniel, West Highland white terrier, and brachycephalic breeds (eg, English bulldog)<sup>18<\/sup><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h3 class=\"left-justified\"><\/h3>\n<h3 class=\"left-justified\"><strong><span class=\"font_purple\">Clinical Signs<\/span><\/strong><\/h3>\n<p class=\"left-justified\"><span class=\"garamond-9-5\">Clinical signs associated with quantitative KCS are listed in <\/span><strong><span class=\"garamond-bold\">Table 3<\/span><\/strong><span class=\"garamond-9-5\">.<\/span><\/p>\n<h3 class=\"left-justified\"><strong><span class=\"font_purple\">Diagnosis<\/span><\/strong><\/h3>\n<p class=\"left-justified\"><span class=\"garamond-9-5\">KCS is diagnosed after consideration of:<\/span><\/p>\n<p class=\"tabs-and-bullets\"><span class=\"helvbold-9-5\">\u2022 <\/span><span class=\"garamond-bold\">History: <\/span><span class=\"garamond-9-5\">Ask historical questions that explore previous drug administration, vaccinations, and surgical procedures.<\/span><\/p>\n<p class=\"tabs-and-bullets\"><span class=\"helvbold-9-5\">\u2022 <\/span><span class=\"garamond-bold\">Ophthalmic Examination: <\/span><span class=\"garamond-9-5\">Perform a complete ophthalmic examination in all dogs presenting with new clinical signs (<\/span><strong><span class=\"garamond-bold\">Table 3<\/span><\/strong><span class=\"garamond-9-5\">) or disease progression.<\/span><\/p>\n<p class=\"tabs-and-bullets\"><span class=\"helvbold-9-5\">\u2022 <\/span><span class=\"garamond-bold\">STT: <\/span><span class=\"garamond-9-5\">This test is the cornerstone of quantitative KCS diagnosis; interpret results in light of clinical signs. A Schirmer tear test 1 (STT1)\u2014performed without application of surface anesthetic agents\u2014assesses reflex tear production. Normal production in dogs is &gt; 15 mm\/min.<\/span><\/p>\n<table border=\"0\" width=\"100%\" cellspacing=\"0\" cellpadding=\"10\">\n<tbody>\n<tr>\n<td bgcolor=\"#fcf4dc\">\n<table border=\"0\" width=\"100%\" cellspacing=\"0\" cellpadding=\"10\">\n<tbody>\n<tr>\n<td class=\"bluboldheader\" align=\"center\" bgcolor=\"#ffffff\">Table 3. Clinical Signs of Quantitative KCS<\/td>\n<\/tr>\n<tr>\n<td bgcolor=\"#daecf3\">\u2022 Thick, adherent mucopurulent discharge (<strong>Figure 1<\/strong>)<br \/>\n\u2022 Conjunctivitis<br \/>\n\u2022 Blepharospasm<br \/>\n\u2022 Dry, lusterless corneal appearance<br \/>\n\u2022 Ulcerative keratitis, ranging from superficial ulcers to perforations (<strong>Figure 2<\/strong>)<br \/>\n\u2022 Corneal pigmentation (<strong>Figures 3 and 4<\/strong>), neovascularization, and\/or keratinization<\/td>\n<\/tr>\n<tr>\n<td bgcolor=\"#ffffff\"><em>Of the breeds predisposed to KCS, many have distichia, physiologic exophthalmia with lagophthalmos, and medial canthal entropion\u2014all conditions that can cause conjunctivitis and keratitis.<\/em><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><a href=\"https:\/\/todaysveterinarypractice.com\/wp-content\/uploads\/sites\/4\/2014\/07\/f01_fig01-04.png\"><img fetchpriority=\"high\" decoding=\"async\" class=\"alignnone size-medium wp-image-6507\" src=\"https:\/\/todaysveterinarypractice.com\/wp-content\/uploads\/sites\/4\/2014\/07\/f01_fig01-04-300x226.png\" alt=\"f01_fig01-04\" width=\"300\" height=\"226\" srcset=\"https:\/\/navc.sitepreview.app\/todaysveterinarypractice.com\/wp-content\/uploads\/sites\/4\/2014\/07\/f01_fig01-04-300x226.png 300w, https:\/\/navc.sitepreview.app\/todaysveterinarypractice.com\/wp-content\/uploads\/sites\/4\/2014\/07\/f01_fig01-04.png 500w\" sizes=\"(max-width: 300px) 100vw, 300px\" \/><\/a><\/p>\n<p><em><strong>Figure 1.<\/strong> Two-year-old castrated male chihuahua. Note corneal neovascularization and pigmentation, thick and adherent mucopurulent discharge, and keratinization of corneal epithelium; STT was 0 mm\/min.<\/em><br \/>\n<em> <strong>Figure 2.<\/strong> Four-year-old castrated male mixed breed dog. Note descemetocele, corneal edema, and mucopurulent ocular discharge; STT was 0 mm\/min.<\/em><br \/>\n<em> <strong>Figure 3.<\/strong> Three-year-old spayed female Shih Tzu. Note corneal neovascularization and mild keratinization; STT was &lt; 5 mm\/min.<\/em><br \/>\n<em> <strong>Figure 4.<\/strong> Three-year-old spayed female Olde English Bulldogge. Note conjunctival hyperemia, corneal neovascularization, pigmentation, keratinization, and thick mucopurulent discharge.<\/em><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2 class=\"indent-125\"><strong><span class=\"bluboldheader\">QUALITATIVE KCS<\/span><\/strong><\/h2>\n<h3 class=\"indent-125\"><strong><span class=\"font_purple\">Causes<\/span><\/strong><\/h3>\n<p class=\"left-justified\"><span class=\"garamond-9-5\">The causes of qualitative tear film deficiency are not completely understood.<\/span><\/p>\n<p class=\"tabs-and-bullets\"><span class=\"helvbold-9-5\">\u2022 <\/span><span class=\"garamond-9-5\">Chronic blepharitis with meibomianitis can lead to decreased production of the lipid layer. Infectious causes of blepharitis include <\/span><span class=\"garamon-italics\">Staphylococcus<\/span><span class=\"garamond-9-5\">, <\/span><span class=\"garamon-italics\">Candida<\/span><span class=\"garamond-9-5\">, and<\/span><span class=\"garamon-italics\">Malassezia<\/span><span class=\"garamond-9-5\"> species.<sup>19<\/sup><\/span><\/p>\n<p class=\"tabs-and-bullets\"><span class=\"helvbold-9-5\">\u2022 <\/span><span class=\"garamond-9-5\">Decreased goblet cell density and subsequent mucin layer deficiency are most likely caused by chronic conjunctival inflammation secondary to infectious disease or immune-mediated disease.<sup>20<\/sup><\/span><\/p>\n<h3 class=\"left-justified\"><strong><span class=\"font_purple\">Clinical Signs<\/span><\/strong><\/h3>\n<p class=\"left-justified\"><span class=\"garamond-9-5\">Clinical signs of qualitative tear film deficiency are more subtle than those seen with quantitative disease, and include:<\/span><\/p>\n<p class=\"tabs-and-bullets\"><span class=\"helvbold-9-5\">\u2022 <\/span><span class=\"garamond-9-5\">Blepharospasm<\/span><\/p>\n<p class=\"tabs-and-bullets\"><span class=\"helvbold-9-5\">\u2022 <\/span><span class=\"garamond-9-5\">Mild corneal neovascularization<\/span><\/p>\n<p class=\"tabs-and-bullets\"><span class=\"helvbold-9-5\">\u2022 <\/span><span class=\"garamond-9-5\">Mucus discharge.<\/span><\/p>\n<p class=\"tabs-and-bullets\"><a href=\"https:\/\/todaysveterinarypractice.com\/wp-content\/uploads\/sites\/4\/2014\/07\/f01_fig05.png\"><img decoding=\"async\" class=\"alignnone wp-image-6508 size-full\" src=\"https:\/\/todaysveterinarypractice.com\/wp-content\/uploads\/sites\/4\/2014\/07\/f01_fig05.png\" alt=\"f01_fig05\" width=\"590\" height=\"400\" srcset=\"https:\/\/navc.sitepreview.app\/todaysveterinarypractice.com\/wp-content\/uploads\/sites\/4\/2014\/07\/f01_fig05.png 590w, https:\/\/navc.sitepreview.app\/todaysveterinarypractice.com\/wp-content\/uploads\/sites\/4\/2014\/07\/f01_fig05-300x203.png 300w\" sizes=\"(max-width: 590px) 100vw, 590px\" \/><\/a><\/p>\n<h3 class=\"left-justified\"><strong><span class=\"font_purple\">Diagnosis<\/span><\/strong><\/h3>\n<p class=\"left-justified\"><span class=\"garamond-9-5\">If qualitative KCS is suspected based on history and clinical signs:<\/span><\/p>\n<ul>\n<li class=\"tabs-and-bullets\"><span class=\"garamond-bold\">STT:<\/span><span class=\"garamond-9-5\"> Perform a STT to <\/span><span class=\"garamon-italics\">rule out<\/span><span class=\"garamond-9-5\"> quantitative aqueous deficiency; STT results are normal in patients with qualitative KCS.<\/span><\/li>\n<li class=\"tabs-and-bullets\"><span class=\"garamond-bold\">TBUT:<\/span><span class=\"garamond-9-5\"> Perform a TBUT to assess for deficiency in the PTF\u2019s mucin component.<\/span><\/li>\n<\/ul>\n<ol>\n<li class=\"tabs-and-bullets\"><span class=\"garamond-9-5\">Apply 1 drop of fluorescein stain to the eye, holding the eyelids open.<\/span><\/li>\n<li class=\"tabs-and-bullets\"><span class=\"garamond-9-5\">Under cobalt-blue illumination, examine the cornea. Note how many seconds it takes for dark spots to appear as the PTF \u201cbreaks up\u201d the fluorescein layer.<\/span><\/li>\n<li class=\"tabs-and-bullets\"><span class=\"garamond-9-5\">A normal TBUT is \u2265 20 seconds. Animals with quantitative deficiencies often have a TBUT of &lt; 5 seconds, which indicates an unstable PTF.<sup>20<\/sup><\/span><\/li>\n<\/ol>\n<ul>\n<li class=\"tabs-and-bullets\"><span class=\"garamond-bold\">Conjunctival Biopsy:<\/span><span class=\"garamond-9-5\"> In cases of suspected mucin deficiency, obtain a conjunctival biopsy specimen to quantitate conjunctival goblet cell density.<\/span><\/li>\n<li class=\"tabs-and-bullets\"><span class=\"garamond-bold\">Eyelid Margin Examination: <\/span><span class=\"garamond-9-5\">With a focus light and magnifying source, carefully examine the eyelid margin to identify deficiencies of the lipid component, which often occur secondary to blepharitis (<\/span><strong><span class=\"garamond-bold\">Figure 6<\/span><\/strong><span class=\"garamond-9-5\">) or meibomianitis.<\/span><\/li>\n<\/ul>\n<p class=\"tabs-and-bullets\"><a href=\"https:\/\/todaysveterinarypractice.com\/wp-content\/uploads\/sites\/4\/2014\/07\/f01_fig06.png\"><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-6509\" src=\"https:\/\/todaysveterinarypractice.com\/wp-content\/uploads\/sites\/4\/2014\/07\/f01_fig06-300x239.png\" alt=\"f01_fig06\" width=\"300\" height=\"239\" \/><\/a><\/p>\n<h2 class=\"left-justified\"><strong><span class=\"bluboldheader\">MEDICAL MANAGEMENT OF KCS<\/span><\/strong><\/h2>\n<p class=\"left-justified\"><span class=\"garamond-9-5\">Primary medical therapy of both quantitative and qualitative KCS consists of tear stimulants and tear replacements. Topical antibiotics and anti-inflammatory drugs are also commonly used.<\/span><\/p>\n<p class=\"indent-125\"><span class=\"garamond-9-5\">Dogs with KCS may have increased sensitivity to pain associated with topical medications, because abnormal PTF cannot provide a reflex dilution effect. This may be especially problematic with frequent application of tear replacement medications that contain preservatives; some artificial tear products are available without preservatives, but the lack of preservatives requires single-use ampules, which most owners find inconvenient.<\/span><\/p>\n<p class=\"indent-125\"><span class=\"garamond-9-5\">In most patients with KCS, topical therapy is required indefinitely. Clients should be educated about the chronicity of KCS and the necessity of lifelong therapy.<\/span><\/p>\n<h3 class=\"left-justified\"><strong><span class=\"font_purple\">Tear Stimulation<\/span><\/strong><\/h3>\n<p class=\"left-justified\"><strong><span class=\"aquaboldtimes\">1. Cyclosporine A (CsA)<\/span><\/strong><\/p>\n<p class=\"left-justified\"><span class=\"garamon-italics\"><em>Mechanism of action.<\/em><\/span><span class=\"garamond-9-5\">Cyclosporine is an immunomodulator that blocks normal production of interleukin-2, which inhibits proliferation of T-helper and cytotoxic T cells in the lacrimal gland and allows normal lacrimation.<sup>21<\/sup><\/span><\/p>\n<p class=\"indent-125\"><span class=\"garamond-9-5\">Cyclosporine also acts as an anti-inflammatory, decreases pigmentation, normalizes goblet cell mucin secretion,<sup>22<\/sup> and directly stimulates lacrimation, but the latter mechanism is still poorly understood.<sup>23<\/sup><\/span><\/p>\n<p><span class=\"garamon-italics\"><em>Efficacy.<\/em><\/span><span class=\"garamond-9-5\">Topical preparations are very effective for tear stimulation and reducing inflammation, with 81.8% of dogs showing improvement (<\/span><strong><span class=\"garamond-bold\">Figure 7<\/span><\/strong><span class=\"garamond-9-5\">).<sup>24,25<\/sup> Dogs with a STT &lt; 2 mm\/min respond with increased tear secretion in approximately 50% of cases, while dogs with a STT \u2265 2 mm\/min have an approximately 80% chance of responding.<sup>18<\/sup><\/span><\/p>\n<p><a href=\"https:\/\/todaysveterinarypractice.com\/wp-content\/uploads\/sites\/4\/2014\/07\/f01_fig07.png\"><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-6510\" src=\"https:\/\/todaysveterinarypractice.com\/wp-content\/uploads\/sites\/4\/2014\/07\/f01_fig07-300x173.png\" alt=\"f01_fig07\" width=\"300\" height=\"173\" srcset=\"https:\/\/navc.sitepreview.app\/todaysveterinarypractice.com\/wp-content\/uploads\/sites\/4\/2014\/07\/f01_fig07-300x173.png 300w, https:\/\/navc.sitepreview.app\/todaysveterinarypractice.com\/wp-content\/uploads\/sites\/4\/2014\/07\/f01_fig07.png 500w\" sizes=\"(max-width: 300px) 100vw, 300px\" \/><\/a><\/p>\n<p class=\"indent-125\"><span class=\"garamon-italics\"><em>Formulation<\/em>.<\/span><span class=\"garamond-9-5\"> CsA is available as Optimmune 0.2% ophthalmic ointment (merck-animal-health-usa.com). Compounded formulations are available in 1% and 2% corn or olive oil solutions; they may be more effective, but may also be more irritating to the eye.<\/span><\/p>\n<p class=\"indent-125\"><span class=\"garamon-italics\">Therapeutic recommendations.<\/span><span class=\"garamond-9-5\"> Apply \u00bc-inch strand of topical CsA Q 12 H, with a recheck STT in 1 month. For optimal results, perform the STT approximately 3 to 4 H after application of CsA. Treatment failure can be diagnosed only after 12 weeks of consistent topical application. If treatment fails, attempt treatment Q 8 H or initiate treatment with tacrolimus.<\/span><\/p>\n<p class=\"indent-125\"><span class=\"garamond-9-5\">With long-term use, CsA decreases corneal pigmentation and vascularization, even in patients that do not experience increased tear production; therefore, its use is often continued in these patients.<sup>18,24<\/sup><\/span><\/p>\n<p class=\"indent-125\"><strong><span class=\"aquaboldtimes\">2. Tacrolimus<\/span><\/strong><\/p>\n<p class=\"left-justified\"><span class=\"garamon-italics\">Mechanism of action. <\/span><span class=\"garamond-9-5\">Tacrolimus has a similar, but more potent, mechanism of action compared with that of CsA.<\/span><\/p>\n<p class=\"indent-125\"><span class=\"garamon-italics\"><em>Efficacy<\/em>. <\/span><span class=\"garamond-9-5\">Patients that are unresponsive to CsA may respond to tacrolimus.<sup>26,27<\/sup><\/span><\/p>\n<p class=\"indent-125\"><span class=\"garamon-italics\"><em>Formulation<\/em>. <\/span><span class=\"garamond-9-5\">Tacrolimus is generally compounded to a 0.03% ophthalmic aqueous suspension; however, formulations may vary.<\/span><\/p>\n<p class=\"indent-125\"><span class=\"garamon-italics\"><em>Therapeutic recommendations<\/em>.<\/span><span class=\"garamond-9-5\"> Apply 1 drop of topical tacrolimus Q 12 H, with a recheck STT in 1 month. Continue treatment for several months before considering treatment failure. In addition to increasing tear production, tacrolimus may decrease clinical signs, such as pigmentation associated with chronic KCS, even if tear production does not increase, but no long-term studies exist.<\/span><\/p>\n<p class=\"indent-125\"><span class=\"garamond-9-5\">Tacrolimus use for treating KCS in dogs is off-label; therefore, the U.S. Food and Drug Administration approved therapy\u2014CsA 0.2% ophthalmic ointment (Optimmune)\u2014 should be used as first-line treatment, with tacrolimus reserved for cases unresponsive to CsA.<\/span><\/p>\n<p class=\"left-justified\"><strong><span class=\"aquaboldtimes\">3. Pilocarpine<\/span><\/strong><\/p>\n<p class=\"left-justified\"><span class=\"garamon-italics\"><em>Mechanism of action<\/em>.<\/span><span class=\"garamond-9-5\"> Parasympathomimetic drug (stimulates or mimics the parasympathetic nervous sytem). Upregulation of parasympathetic receptors secondary to denervation results in increased sensitivity of the lacrimal system to pilocarpine when compared with the rest of the body.<sup>9<\/sup><\/span><\/p>\n<p class=\"indent-125\"><span class=\"garamon-italics\"><em>Efficacy<\/em>.<\/span><span class=\"garamond-9-5\"> May be used to stimulate tear production in cases of neurogenic (quantitative) KCS. These cases are diagnosed when ipsilateral dry nose is present in conjunction with a low result on STT.<\/span><\/p>\n<p class=\"indent-125\"><span class=\"garamon-italics\"><em>Formulation<\/em>.<\/span><span class=\"garamond-9-5\"> 1% or 2% solutions<\/span><\/p>\n<p class=\"indent-125\"><span class=\"garamon-italics\"><em>Therapeutic recommendations<\/em>.<\/span><span class=\"garamond-9-5\"> Sprinkle 1 to 2 drops of 2% pilocarpine per 10 kg on top of food Q 12 H. Systemic administration of pilocarpine is preferred because it can be irritating when applied topically.<sup>28<\/sup><\/span><\/p>\n<p class=\"indent-125\"><span class=\"garamond-9-5\">Note that pilocarpine has a narrow therapeutic window, and while some clinicians advocate increasing the number of drops applied to food by 1 drop each day until systemic adverse effects are observed\u2014such as vomiting, diarrhea, ptyalism, anorexia, and bradycardia\u2014we prefer to avoid these effects by only increasing the total dose by 1 or 2 drops before considering pilocarpine ineffective. Client education about adverse effects is important.<\/span><\/p>\n<h3 class=\"left-justified\"><strong><span class=\"font_purple\">Tear Replacement<\/span><\/strong><\/h3>\n<p class=\"left-justified\"><span class=\"garamond-9-5\">Tear replacement therapy provides lubrication until tear stimulants are effective. Lifelong tear replacement therapy may be needed in dogs that never respond to CsA or tacrolimus. These medications are available as solutions, gels, and ointments, and have a wide variety of constituents.<\/span><\/p>\n<ol>\n<li class=\"left-justified\"><span class=\"aquaboldtimes\">Artificial tear solutions<\/span><span class=\"garamond-9-5\"> commonly contain 0.1% to 1.4% polyvinyl alcohol. Artificial tear solutions are useful for removing debris and mucus from the ocular surface; however, they are not feasible as monotherapy in most dogs with KCS due to the need for frequent application in order to achieve adequate lubrication.<\/span><\/li>\n<li class=\"left-justified\"><span class=\"aquaboldtimes\">Cellulose-based solutions\/gels and viscoelastic products<\/span><span class=\"garamond-9-5\"> are more viscous and have slower evaporation times than artificial tear solutions. They require application Q 4 to 6 H. Examples of cellulose-based solution and viscoelastic products are hydroxypropyl and hyaluronate, respectively.<\/span><\/li>\n<li class=\"left-justified\"><span class=\"aquaboldtimes\">Artificial tear formulations containing petrolatum, mineral oil, or lanolin<\/span><span class=\"garamond-9-5\"> are the most viscous products and provide long-term lubrication, but can result in debris accumulation. They are best suited for patients with:<\/span><\/li>\n<\/ol>\n<ul>\n<li class=\"tabs-and-bullets\"><span class=\"garamond-9-5\">Lipid layer deficiencies<\/span><\/li>\n<li class=\"tabs-and-bullets\"><span class=\"garamond-9-5\">Lagophthalmos (administered prior to sleep)<\/span><\/li>\n<li class=\"tabs-and-bullets\"><span class=\"garamond-9-5\">Owners who will be absent for long periods.<\/span><\/li>\n<\/ul>\n<h3 class=\"indent-125\"><strong><span class=\"font_purple\">Antibiotics<\/span><\/strong><\/h3>\n<p class=\"indent-125\"><span class=\"garamond-9-5\">A severe, mucopurulent discharge suggests a secondary bacterial infection. Generally, use a broad-spectrum ophthalmic antibiotic, such as triple antibiotic ointment (neomycin\/bacitracin\/polymyxin B) Q 6 to 8 H for approximately 2 weeks. If empirical treatment fails to resolve the discharge, perform culture and sensitivity.<\/span><\/p>\n<h3 class=\"indent-125\"><strong><span class=\"font_purple\">Anti-Inflammatory Agents<\/span><\/strong><\/h3>\n<p class=\"indent-125\"><span class=\"garamond-9-5\">Anti-inflammatory therapy may be useful if conjunctival inflammation is severe, possibly occluding lacrimal excretory ducts. Corticosteroids can be used on a short-term basis (1\u20134 weeks); discontinue if patient is nonresponsive. Only consider using them, though, in animals with no uptake of fluorescein dye.<\/span><\/p>\n<p class=\"indent-125\"><span class=\"garamond-9-5\">Apply topical prednisolone acetate 1% or dexamethasone 0.1% topically Q 6 to 8 H. Use caution when using topical corticosteroids because dogs with KCS can develop ulcerative keratitis, infection, and keratomalacia.<\/span><\/p>\n<h3 class=\"indent-125\"><strong><span class=\"font_purple\">Mucolytics<\/span><\/strong><\/h3>\n<p class=\"indent-125\"><span class=\"garamond-9-5\">If a patient with KCS has copious mucopurulent discharge, acetylcysteine 5% is often administered; however, its use is not common due to its expense and toxicity to the epithelium. In addition, the mucous layer provides some protection to the cornea. Frequent flushing with sterile eyewash, instead, simply removes mucus without side effects.<\/span><\/p>\n<h2 class=\"indent-125\"><strong><span class=\"bluboldheader\">SURGICAL MANAGEMENT OF KCS<\/span><\/strong><\/h2>\n<p><span class=\"garamond-9-5\">After 3 to 6 months of medical therapy with no response, surgical treatment for KCS can be considered. Surgery is not always successful and, even when it is, patients often need ongoing topical therapy.<sup>29<\/sup><\/span><\/p>\n<h3 class=\"indent-125\"><strong><span class=\"font_purple\">Treatment of Choice<\/span><\/strong><\/h3>\n<p class=\"indent-125\"><span class=\"garamond-9-5\">Parotid duct transposition\u2014in which the parotid duct and papilla are dissected free of the oral mucosa, mobilized, and transposed to the inferior cul-de-sac\u2014is the surgical treatment of choice. Open and closed methods have been described.<\/span><\/p>\n<h3 class=\"indent-125\"><strong><span class=\"font_purple\">Challenges<\/span><\/strong><\/h3>\n<p class=\"indent-125\"><span class=\"garamond-9-5\">This surgery is often performed by a board-certified ophthalmologist due to the difficulty of the procedure in some dogs and often complicated aftercare. Potential complications include severance of the duct, occlusion of the duct secondary to scar formation, development of white mineral crystalline corneal deposits, facial dermatitis, periocular pyoderma, and excessive saliva production.<\/span><\/p>\n<div class=\"orange-box\">\n<h2>Ulcer Therapy<\/h2>\n<p>While superficial, uncomplicated ulcers can be treated with triple antibiotic ointment, CsA, and lubricants, ulcers secondary to KCS are usually complicated and require more intensive therapy.<br \/>\n1. Perform culture and cytologyon stromal ulcers and ulcers with a cellular infiltrate.<\/p>\n<p>2. Apply topical antibiotics Q 2 H to infected ulcers until the cornea stabilizes. Appropriate antibiotics include:<\/p>\n<ul>\n<li>Ciprofloxacin 0.03% ophthalmic solution, or other ophthalmic fluoroquinolones, used alone <em><strong>or<\/strong><\/em><\/li>\n<li>Tobramycin 0.03% ophthalmic solution <em><strong>and<\/strong><\/em> cefazolin (33 mg\/mL in artificial tear solution).<\/li>\n<\/ul>\n<p>3. Use topical atropine to dilate the pupil and decrease ciliary spasm, even though it is associated with decreased tear production. If the patient remains uncomfortable while on atropine therapy, the addition of oral NSAIDs may be considered.<\/p>\n<p>4. Consider conjunctival graft placement in addition to KCS therapy and frequent antibiotic therapy for deep ulcers.<\/p>\n<\/div>\n<h2 class=\"indent-125\"><strong><span class=\"bluboldheader\">PROGNOSIS &amp; MONITORING<\/span><\/strong><\/h2>\n<p class=\"indent-125\"><span class=\"garamond-9-5\">Prognosis depends on the underlying etiology of KCS and the patient\u2019s response to treatment (<\/span><span class=\"garamond-bold\">Table 2<\/span><span class=\"garamond-9-5\">). If KCS does not respond to medical therapy, the prognosis is worse for vision retention. In addition, most patients will require lifelong therapy with topical immunosuppressive medications.<\/span><\/p>\n<p class=\"indent-125\"><span class=\"garamond-9-5\">Recently, chronic keratitis treated long-term with tacrolimus or CsA has been tenuously associated with increased risk for corneal squamous cell carcinoma.<sup>30<\/sup> However, because the study was retrospective, clinical data are lacking, and KCS alone may have resulted in a predisposition to this condition. While this study is interesting, KCS should be treated as described in this article.<\/span><\/p>\n<p class=\"indent-125\"><span class=\"garamond-9-5\">Dogs with a diagnosis of KCS should be evaluated every 6 to 12 months to assess effect of treatment and progression of disease.<\/span><\/p>\n<p class=\"no-indent-\"><span class=\"helvetica-9-pt\">CsA = cyclosporine A; KCS = keratoconjunctivitis sicca; PTF = precorneal tear film; STT = Schirmer tear test; STT1 = Schirmer tear test 1; TBUT = tear film breakup time<\/span><\/p>\n<h3>References<\/h3>\n<ol>\n<li class=\"references\">King-Smith PE, Fink BA, Fogt N, et al. The thickness of the human precorneal tear film: Evidence from reflection spectra. <span class=\"refersitalics\"><em>Invest Ophthalmol Vis Sci<\/em> 2000; 41(11):3348-3359.<\/span><\/li>\n<li class=\"references\">Prydall JI, Artal P, Wood H, Campbell FW. Study of human precorneal tear film thickness and structure using laser interferometry. <em><span class=\"refersitalics\">Invest Ophthalmol Vis Sci<\/span><\/em> 1992; 33(6):2006-2011.<\/li>\n<li class=\"references\">Franzco IC. Fluids of the ocular surface: Concepts, functions, and physics. <em><span class=\"refersitalics\">Clin Exp Ophthalmol<\/span><\/em> 2012; 40(6):634-643.<\/li>\n<li class=\"references\">Herring IP, Pickett JP, Champagne ES, Marini M. Evaluation of aqueous tear production in dogs following general anesthesia. <span class=\"refersitalics\"><em>JAAHA<\/em> 2000; 36(5):427-430.<\/span><\/li>\n<li class=\"references\">Dodam JR, Branson KR, Martin DD. Effects of intramuscular sedative and opioid combinations on tear production in dogs. <em><span class=\"refersitalics\">Vet Ophthalmol<\/span><\/em> 1998; 1(1):57-59.<\/li>\n<li class=\"references\">Sanchez RF, Mellor D, Mould J. Effects of medetomidine and medetomidine-butorphanol combination on Schirmer tear test 1 readings in dogs. <span class=\"refersitalics\"><em>Vet Ophthalmol<\/em> 2006; 9(1):33-37.<\/span><\/li>\n<li class=\"references\">Kaswan RL, Martin CL, Chapman WL. Keratoconjunctivitis sicca: Histopathologic study of nictitating membrane and lacrimal glands from 28 dogs. <em><span class=\"refersitalics\">Am J Vet Res<\/span><\/em> 1984; 45(1):112-118.<\/li>\n<li class=\"references\">Martin CL, Kaswan R. Distemper-associated keratoconjunctivitis sicca. <em><span class=\"refersitalics\">JAAHA<\/span><\/em> 1985; 21(3):355-359.<\/li>\n<li class=\"references\">Matheis FL, Walder-Reinhardt L, Spiess BM. Canine neurogenic keratoconjunctivitis sicca: 11 cases (2006-2010). <em><span class=\"refersitalics\">Vet Ophthalmol<\/span><\/em> 2012; 15(4):288-290.<\/li>\n<li class=\"references\">Naranjo C, Fondevila D, Leiva M, et al. Characterization of lacrimal gland lesions and possible pathogenic mechanisms of keratoconjunctivitis sicca in dogs with leishmaniosis. <span class=\"refersitalics\"><em>Vet Parasit<\/em> 2005; 133(1):37-47.<\/span><\/li>\n<li class=\"references\">Westermeyer HD, Ward DA, Abrams K. Breed predisposition to congenital alacrima in dogs. <span class=\"refersitalics\"><em>Vet Ophthalmol<\/em> 2009; 12(1):1-5.<\/span><\/li>\n<li class=\"references\">Klauss G, Giuliano EA, Moore CP, et al. Keratoconjunctivitis sicca associated with administration of etodolac in dogs: 211 cases (1992-2002). <em><span class=\"refersitalics\">JAVMA<\/span><\/em> 2007; 230(4):541-547.<\/li>\n<li class=\"references\">Trepanier LA, Danhoff R, Troll J, Watrous D. Clinical findings in 40 dogs with hypersensitivity associated with administration of potentiated sulfonamides. <em><span class=\"refersitalics\">J Vet Intern Med<\/span><\/em> 2003; 17(5):647-652.<\/li>\n<li class=\"references\">Bryan GM, Slatter DH. Keratoconjunctivitis sicca induced by phenazopyridine in dogs. <span class=\"refersitalics\"><em>Arch Ophthalmol<\/em> 1973; 90(4):310-311.<\/span><\/li>\n<li class=\"references\">Saito A, Izumisawa Y, Yamashita K, Kotani T. The effect of third eyelid gland removal on the ocular surface of dogs. <span class=\"refersitalics\"><em>Vet Ophthalmol<\/em> 2001; 4(1):13-18.<\/span><\/li>\n<li class=\"references\">Spugnini EP, Thrall DE, Price S, et al. Primary irradiation of canine intracranial masses. <span class=\"refersitalics\"><em>Vet Radiol Ultrasound<\/em> 2000; 41(4):377-380.<\/span><\/li>\n<li class=\"references\">Sansom J, Barnett KC. Keratoconjunctivitis sicca in the dog: A review of two hundred cases.<span class=\"refersitalics\"><em> J Small Anim Pract<\/em> 1985; 26(3):121-131.<\/span><\/li>\n<li class=\"references\">Kaswan RL, Salisbury MA. A new perspective on canine keratoconjunctivitis sicca. Treatment with ophthalmic cyclosporine. <span class=\"refersitalics\"><em>Vet Clin North Am Small Anim Pract<\/em> 1990; 20(3):583-613.<\/span><\/li>\n<li class=\"references\">Moore CP. Qualitative tear film disease. <span class=\"refersitalics\"><em>Vet Clin North Am Sm Anim Pract<\/em> 1990; 20(3):565-581.<\/span><\/li>\n<li class=\"references\">Moore CP, Collier LL. Ocular surface disease associated with the loss of conjunctival goblet cells in dogs. <span class=\"refersitalics\"><em>JAAHA<\/em> 1990; 26(5):458-465.<\/span><\/li>\n<li class=\"references\">Hess AD. Mechanisms of action of cyclosporine: Considerations for treatment of autoimmune diseases. <em><span class=\"refersitalics\">Clin Immunol Immunopathol <\/span><\/em>1993; 68(2):220-228.Moore CP, McHugh JB, Thorne JG, Phillips TE. Effect of cyclosporine on conjunctival mucin in a canine keratoconjunctivitis sicca model. <span class=\"refersitalics\">Invest Ophthalmol Vis Sci 2001; 42(3):653-659.<\/span><\/li>\n<li class=\"references\">Palmer SL, Bowen PA, Green K. Tear flow in cyclosporine recipients. <em><span class=\"refersitalics\">Ophthalmol<\/span><\/em> 1995; 102(1):118-121.<\/li>\n<li class=\"references\">Olivero DK, Davidson MG, English RV, et al. Clinical evaluation of 1% cyclosporine for topical treatment of keratoconjunctivitis sicca in dogs. <em><span class=\"refersitalics\">JAVMA<\/span><\/em> 1991; 199(8):1039-1042.<\/li>\n<li class=\"references\">Morgan RV, Abrams KL. Topical administration of cyclosporine for treatment of keratoconjunctivitis sicca in dogs. <em><span class=\"refersitalics\">JAVMA<\/span><\/em> 1991; 199(8):1043-1046.<\/li>\n<li class=\"references\">Berdoulay A, English RV, Nadelstein B. Effect of topical 0.02% tacrolimus aqueous suspension on tear production in dogs with keratoconjunctivitis sicca. <span class=\"refersitalics\"><em>Vet Ophthalmol<\/em> 2005; 8(4):225-232.<\/span><\/li>\n<li class=\"references\">Hendrix DVH, Adkins EA, Ward DA, et al. An investigation comparing the efficacy of topical ocular application of tacrolimus and cyclosporine in dogs. <em><span class=\"refersitalics\">Vet Med Inter<\/span><\/em> 2011; 2011:487592.<\/li>\n<li class=\"references\">Smith EM, Buyukmihci NC, Faryer TB. Effect of topical pilocarpine treatment on tear production in dogs. <em><span class=\"refersitalics\">JAVMA<\/span><\/em> 1994; 205(9):1286-1289.<\/li>\n<li class=\"references\">Rhodes M, Heinrich C, Featherstone H, et al. Parotid duct transposition in dogs: A retrospective review of 92 eyes from 1999-2009. <span class=\"refersitalics\"><em>Vet Ophthalmol<\/em> 2012; 15(4):213-222.<\/span><\/li>\n<li class=\"references\">Dreyfus J, Schobert CS, Dubielzig RR. Superficial corneal squamous cell carcinoma occurring in dogs with chronic keratitis. <em><span class=\"refersitalics\">Vet Ophthalmol<\/span> <\/em>2011; 14(13):161-168.<\/li>\n<\/ol>\n<p><span class=\"author-bio\"><strong><a href=\"https:\/\/todaysveterinarypractice.com\/wp-content\/uploads\/sites\/4\/2014\/07\/f01_Best.png\"><img loading=\"lazy\" decoding=\"async\" class=\"alignleft wp-image-6506\" src=\"https:\/\/todaysveterinarypractice.com\/wp-content\/uploads\/sites\/4\/2014\/07\/f01_Best.png\" alt=\"f01_Best\" width=\"79\" height=\"91\" \/><\/a>Lori J. Best<\/strong>, DVM, is a first-year ophthalmology resident at University of Tennessee College of Veterinary Medicine. She received her DVM from Colorado State University and completed her small animal rotating internship at University of Tennessee.<\/span><\/p>\n<p>&nbsp;<\/p>\n<p><span class=\"author-bio\"><strong><a href=\"https:\/\/todaysveterinarypractice.com\/wp-content\/uploads\/sites\/4\/2014\/07\/f02_Hendrix.png\"><img loading=\"lazy\" decoding=\"async\" class=\"alignleft wp-image-6511\" src=\"https:\/\/todaysveterinarypractice.com\/wp-content\/uploads\/sites\/4\/2014\/07\/f02_Hendrix.png\" alt=\"f02_Hendrix\" width=\"78\" height=\"90\" \/><\/a>Diane V.H. Hendrix<\/strong>, DVM, Diplomate ACVO, is a professor of ophthalmology at University of Tennessee College of Veterinary Medicine. She received the Zoetis Distinguished Veterinary Teaching Award in 2013. Dr. Hendrix received her DVM from University of Tennessee and completed her residency in comparative ophthalmology at University of Florida.<br \/>\n<\/span><\/p>\n<p>&nbsp;<\/p>\n<p><span class=\"author-bio\"><strong><a href=\"https:\/\/todaysveterinarypractice.com\/wp-content\/uploads\/sites\/4\/2014\/07\/f02_Ward.png\"><img loading=\"lazy\" decoding=\"async\" class=\"alignleft wp-image-6512\" src=\"https:\/\/todaysveterinarypractice.com\/wp-content\/uploads\/sites\/4\/2014\/07\/f02_Ward.png\" alt=\"f02_Ward\" width=\"82\" height=\"94\" \/><\/a>Dan A. Ward<\/strong>, DVM, PhD, Diplomate ACVO, is a professor of ophthalmology at University of Tennessee College of Veterinary Medicine. He received the Pfizer Distinguished Professor Award in 2012. Dr. Ward received his DVM from University of Tennessee and completed his ophthalmology residency, PhD in pharmacology, and postdoctoral work in clinical pharmacology at University of Georgia.<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Lori J.<\/p>\n","protected":false},"author":1,"featured_media":3049,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"iawp_total_views":20179,"footnotes":""},"categories":[367],"tags":[13],"class_list":["post-1013","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-july-august-2014","tag-peer-reviewed","column-features","clinical_topics-ophthalmology"],"acf":{"hide_sidebar":false,"hide_sidebar_ad":false,"hide_all_ads":false},"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v24.7 (Yoast SEO v27.3) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Diagnosis &amp; Treatment of Keratoconjunctivitis Sicca in Dogs<\/title>\n<meta name=\"description\" content=\"Keratoconjunctivitis sicca (KCS), is a relatively common condition in dogs, although the diagnosis is often overlooked. This article provides guidance on the pathophysiology, causes, diagnosis, and medical and surgical treatment for this condition.\" \/>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Diagnosis &amp; Treatment of Keratoconjunctivitis Sicca in Dogs\" \/>\n<meta property=\"og:description\" content=\"Keratoconjunctivitis sicca (KCS), is a relatively common condition in dogs, although the diagnosis is often overlooked. This article provides guidance on the pathophysiology, causes, diagnosis, and medical and surgical treatment for this condition.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/navc.sitepreview.app\/todaysveterinarypractice.com\/ophthalmology\/diagnosis-treatment-of-keratoconjunctivitis-sicca-in-dogs\/\" \/>\n<meta property=\"og:site_name\" content=\"Today&#039;s Veterinary Practice\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/todaysveterinarypractice\" \/>\n<meta property=\"article:published_time\" content=\"2014-07-01T00:33:42+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-02-16T15:55:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/navc.sitepreview.app\/todaysveterinarypractice.com\/wp-content\/uploads\/sites\/4\/2014\/03\/Figure-6_header.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"800\" \/>\n\t<meta property=\"og:image:height\" content=\"540\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"17 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/navc.sitepreview.app\\\/todaysveterinarypractice.com\\\/ophthalmology\\\/diagnosis-treatment-of-keratoconjunctivitis-sicca-in-dogs\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/navc.sitepreview.app\\\/todaysveterinarypractice.com\\\/ophthalmology\\\/diagnosis-treatment-of-keratoconjunctivitis-sicca-in-dogs\\\/\"},\"author\":{\"name\":\"\",\"@id\":\"\"},\"headline\":\"Diagnosis &amp; Treatment of Keratoconjunctivitis Sicca in Dogs\",\"datePublished\":\"2014-07-01T00:33:42+00:00\",\"dateModified\":\"2022-02-16T15:55:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/navc.sitepreview.app\\\/todaysveterinarypractice.com\\\/ophthalmology\\\/diagnosis-treatment-of-keratoconjunctivitis-sicca-in-dogs\\\/\"},\"wordCount\":3467,\"commentCount\":3,\"publisher\":{\"@id\":\"https:\\\/\\\/navc.sitepreview.app\\\/todaysveterinarypractice.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/navc.sitepreview.app\\\/todaysveterinarypractice.com\\\/ophthalmology\\\/diagnosis-treatment-of-keratoconjunctivitis-sicca-in-dogs\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/navc.sitepreview.app\\\/todaysveterinarypractice.com\\\/wp-content\\\/uploads\\\/sites\\\/4\\\/2014\\\/03\\\/Figure-6_header.jpg\",\"keywords\":[\"Peer Reviewed\"],\"articleSection\":[\"July\\\/August 2014\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/navc.sitepreview.app\\\/todaysveterinarypractice.com\\\/ophthalmology\\\/diagnosis-treatment-of-keratoconjunctivitis-sicca-in-dogs\\\/#respond\"]}]},{\"@type\":[\"WebPage\",\"MedicalWebPage\"],\"@id\":\"https:\\\/\\\/navc.sitepreview.app\\\/todaysveterinarypractice.com\\\/ophthalmology\\\/diagnosis-treatment-of-keratoconjunctivitis-sicca-in-dogs\\\/\",\"url\":\"https:\\\/\\\/navc.sitepreview.app\\\/todaysveterinarypractice.com\\\/ophthalmology\\\/diagnosis-treatment-of-keratoconjunctivitis-sicca-in-dogs\\\/\",\"name\":\"Diagnosis & Treatment of Keratoconjunctivitis Sicca in Dogs\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/navc.sitepreview.app\\\/todaysveterinarypractice.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/navc.sitepreview.app\\\/todaysveterinarypractice.com\\\/ophthalmology\\\/diagnosis-treatment-of-keratoconjunctivitis-sicca-in-dogs\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/navc.sitepreview.app\\\/todaysveterinarypractice.com\\\/ophthalmology\\\/diagnosis-treatment-of-keratoconjunctivitis-sicca-in-dogs\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/navc.sitepreview.app\\\/todaysveterinarypractice.com\\\/wp-content\\\/uploads\\\/sites\\\/4\\\/2014\\\/03\\\/Figure-6_header.jpg\",\"datePublished\":\"2014-07-01T00:33:42+00:00\",\"dateModified\":\"2022-02-16T15:55:14+00:00\",\"description\":\"Keratoconjunctivitis sicca (KCS), is a relatively common condition in dogs, although the diagnosis is often overlooked. This article provides guidance on the pathophysiology, causes, diagnosis, and medical and surgical treatment for this condition.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/navc.sitepreview.app\\\/todaysveterinarypractice.com\\\/ophthalmology\\\/diagnosis-treatment-of-keratoconjunctivitis-sicca-in-dogs\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/navc.sitepreview.app\\\/todaysveterinarypractice.com\\\/ophthalmology\\\/diagnosis-treatment-of-keratoconjunctivitis-sicca-in-dogs\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/navc.sitepreview.app\\\/todaysveterinarypractice.com\\\/ophthalmology\\\/diagnosis-treatment-of-keratoconjunctivitis-sicca-in-dogs\\\/#primaryimage\",\"url\":\"https:\\\/\\\/navc.sitepreview.app\\\/todaysveterinarypractice.com\\\/wp-content\\\/uploads\\\/sites\\\/4\\\/2014\\\/03\\\/Figure-6_header.jpg\",\"contentUrl\":\"https:\\\/\\\/navc.sitepreview.app\\\/todaysveterinarypractice.com\\\/wp-content\\\/uploads\\\/sites\\\/4\\\/2014\\\/03\\\/Figure-6_header.jpg\",\"width\":800,\"height\":540},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/navc.sitepreview.app\\\/todaysveterinarypractice.com\\\/ophthalmology\\\/diagnosis-treatment-of-keratoconjunctivitis-sicca-in-dogs\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/navc.sitepreview.app\\\/todaysveterinarypractice.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Diagnosis &amp; Treatment of Keratoconjunctivitis Sicca in Dogs\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/navc.sitepreview.app\\\/todaysveterinarypractice.com\\\/#website\",\"url\":\"https:\\\/\\\/navc.sitepreview.app\\\/todaysveterinarypractice.com\\\/\",\"name\":\"Today's Veterinary Practice\",\"description\":\"Peer-Reviewed Veterinary Journal\",\"publisher\":{\"@id\":\"https:\\\/\\\/navc.sitepreview.app\\\/todaysveterinarypractice.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/navc.sitepreview.app\\\/todaysveterinarypractice.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/navc.sitepreview.app\\\/todaysveterinarypractice.com\\\/#organization\",\"name\":\"Today's Veterinary Practice\",\"url\":\"https:\\\/\\\/navc.sitepreview.app\\\/todaysveterinarypractice.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/navc.sitepreview.app\\\/todaysveterinarypractice.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/todaysveterinarypractice.com\\\/wp-content\\\/uploads\\\/sites\\\/4\\\/2022\\\/01\\\/tvp-logo.png\",\"contentUrl\":\"https:\\\/\\\/todaysveterinarypractice.com\\\/wp-content\\\/uploads\\\/sites\\\/4\\\/2022\\\/01\\\/tvp-logo.png\",\"width\":179,\"height\":89,\"caption\":\"Today's Veterinary Practice\"},\"image\":{\"@id\":\"https:\\\/\\\/navc.sitepreview.app\\\/todaysveterinarypractice.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/todaysveterinarypractice\",\"https:\\\/\\\/www.youtube.com\\\/thenavc\"],\"email\":\"info@navc.com\"},{\"@type\":\"Person\",\"@id\":\"\",\"url\":\"https:\\\/\\\/navc.sitepreview.app\\\/todaysveterinarypractice.com\\\/author\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Diagnosis & Treatment of Keratoconjunctivitis Sicca in Dogs","description":"Keratoconjunctivitis sicca (KCS), is a relatively common condition in dogs, although the diagnosis is often overlooked. This article provides guidance on the pathophysiology, causes, diagnosis, and medical and surgical treatment for this condition.","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"en_US","og_type":"article","og_title":"Diagnosis &amp; Treatment of Keratoconjunctivitis Sicca in Dogs","og_description":"Keratoconjunctivitis sicca (KCS), is a relatively common condition in dogs, although the diagnosis is often overlooked. This article provides guidance on the pathophysiology, causes, diagnosis, and medical and surgical treatment for this condition.","og_url":"https:\/\/navc.sitepreview.app\/todaysveterinarypractice.com\/ophthalmology\/diagnosis-treatment-of-keratoconjunctivitis-sicca-in-dogs\/","og_site_name":"Today&#039;s Veterinary Practice","article_publisher":"https:\/\/www.facebook.com\/todaysveterinarypractice","article_published_time":"2014-07-01T00:33:42+00:00","article_modified_time":"2022-02-16T15:55:14+00:00","og_image":[{"width":800,"height":540,"url":"https:\/\/navc.sitepreview.app\/todaysveterinarypractice.com\/wp-content\/uploads\/sites\/4\/2014\/03\/Figure-6_header.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_misc":{"Written by":"","Est. reading time":"17 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/navc.sitepreview.app\/todaysveterinarypractice.com\/ophthalmology\/diagnosis-treatment-of-keratoconjunctivitis-sicca-in-dogs\/#article","isPartOf":{"@id":"https:\/\/navc.sitepreview.app\/todaysveterinarypractice.com\/ophthalmology\/diagnosis-treatment-of-keratoconjunctivitis-sicca-in-dogs\/"},"author":{"name":"","@id":""},"headline":"Diagnosis &amp; Treatment of Keratoconjunctivitis Sicca in Dogs","datePublished":"2014-07-01T00:33:42+00:00","dateModified":"2022-02-16T15:55:14+00:00","mainEntityOfPage":{"@id":"https:\/\/navc.sitepreview.app\/todaysveterinarypractice.com\/ophthalmology\/diagnosis-treatment-of-keratoconjunctivitis-sicca-in-dogs\/"},"wordCount":3467,"commentCount":3,"publisher":{"@id":"https:\/\/navc.sitepreview.app\/todaysveterinarypractice.com\/#organization"},"image":{"@id":"https:\/\/navc.sitepreview.app\/todaysveterinarypractice.com\/ophthalmology\/diagnosis-treatment-of-keratoconjunctivitis-sicca-in-dogs\/#primaryimage"},"thumbnailUrl":"https:\/\/navc.sitepreview.app\/todaysveterinarypractice.com\/wp-content\/uploads\/sites\/4\/2014\/03\/Figure-6_header.jpg","keywords":["Peer Reviewed"],"articleSection":["July\/August 2014"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/navc.sitepreview.app\/todaysveterinarypractice.com\/ophthalmology\/diagnosis-treatment-of-keratoconjunctivitis-sicca-in-dogs\/#respond"]}]},{"@type":["WebPage","MedicalWebPage"],"@id":"https:\/\/navc.sitepreview.app\/todaysveterinarypractice.com\/ophthalmology\/diagnosis-treatment-of-keratoconjunctivitis-sicca-in-dogs\/","url":"https:\/\/navc.sitepreview.app\/todaysveterinarypractice.com\/ophthalmology\/diagnosis-treatment-of-keratoconjunctivitis-sicca-in-dogs\/","name":"Diagnosis & Treatment of Keratoconjunctivitis Sicca in Dogs","isPartOf":{"@id":"https:\/\/navc.sitepreview.app\/todaysveterinarypractice.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/navc.sitepreview.app\/todaysveterinarypractice.com\/ophthalmology\/diagnosis-treatment-of-keratoconjunctivitis-sicca-in-dogs\/#primaryimage"},"image":{"@id":"https:\/\/navc.sitepreview.app\/todaysveterinarypractice.com\/ophthalmology\/diagnosis-treatment-of-keratoconjunctivitis-sicca-in-dogs\/#primaryimage"},"thumbnailUrl":"https:\/\/navc.sitepreview.app\/todaysveterinarypractice.com\/wp-content\/uploads\/sites\/4\/2014\/03\/Figure-6_header.jpg","datePublished":"2014-07-01T00:33:42+00:00","dateModified":"2022-02-16T15:55:14+00:00","description":"Keratoconjunctivitis sicca (KCS), is a relatively common condition in dogs, although the diagnosis is often overlooked. This article provides guidance on the pathophysiology, causes, diagnosis, and medical and surgical treatment for this condition.","breadcrumb":{"@id":"https:\/\/navc.sitepreview.app\/todaysveterinarypractice.com\/ophthalmology\/diagnosis-treatment-of-keratoconjunctivitis-sicca-in-dogs\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/navc.sitepreview.app\/todaysveterinarypractice.com\/ophthalmology\/diagnosis-treatment-of-keratoconjunctivitis-sicca-in-dogs\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/navc.sitepreview.app\/todaysveterinarypractice.com\/ophthalmology\/diagnosis-treatment-of-keratoconjunctivitis-sicca-in-dogs\/#primaryimage","url":"https:\/\/navc.sitepreview.app\/todaysveterinarypractice.com\/wp-content\/uploads\/sites\/4\/2014\/03\/Figure-6_header.jpg","contentUrl":"https:\/\/navc.sitepreview.app\/todaysveterinarypractice.com\/wp-content\/uploads\/sites\/4\/2014\/03\/Figure-6_header.jpg","width":800,"height":540},{"@type":"BreadcrumbList","@id":"https:\/\/navc.sitepreview.app\/todaysveterinarypractice.com\/ophthalmology\/diagnosis-treatment-of-keratoconjunctivitis-sicca-in-dogs\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/navc.sitepreview.app\/todaysveterinarypractice.com\/"},{"@type":"ListItem","position":2,"name":"Diagnosis &amp; Treatment of Keratoconjunctivitis Sicca in Dogs"}]},{"@type":"WebSite","@id":"https:\/\/navc.sitepreview.app\/todaysveterinarypractice.com\/#website","url":"https:\/\/navc.sitepreview.app\/todaysveterinarypractice.com\/","name":"Today's Veterinary Practice","description":"Peer-Reviewed Veterinary Journal","publisher":{"@id":"https:\/\/navc.sitepreview.app\/todaysveterinarypractice.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/navc.sitepreview.app\/todaysveterinarypractice.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/navc.sitepreview.app\/todaysveterinarypractice.com\/#organization","name":"Today's Veterinary Practice","url":"https:\/\/navc.sitepreview.app\/todaysveterinarypractice.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/navc.sitepreview.app\/todaysveterinarypractice.com\/#\/schema\/logo\/image\/","url":"https:\/\/todaysveterinarypractice.com\/wp-content\/uploads\/sites\/4\/2022\/01\/tvp-logo.png","contentUrl":"https:\/\/todaysveterinarypractice.com\/wp-content\/uploads\/sites\/4\/2022\/01\/tvp-logo.png","width":179,"height":89,"caption":"Today's Veterinary Practice"},"image":{"@id":"https:\/\/navc.sitepreview.app\/todaysveterinarypractice.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/todaysveterinarypractice","https:\/\/www.youtube.com\/thenavc"],"email":"info@navc.com"},{"@type":"Person","@id":"","url":"https:\/\/navc.sitepreview.app\/todaysveterinarypractice.com\/author\/"}]}},"_links":{"self":[{"href":"https:\/\/navc.sitepreview.app\/todaysveterinarypractice.com\/wp-json\/wp\/v2\/posts\/1013","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/navc.sitepreview.app\/todaysveterinarypractice.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/navc.sitepreview.app\/todaysveterinarypractice.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/navc.sitepreview.app\/todaysveterinarypractice.com\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/navc.sitepreview.app\/todaysveterinarypractice.com\/wp-json\/wp\/v2\/comments?post=1013"}],"version-history":[{"count":1,"href":"https:\/\/navc.sitepreview.app\/todaysveterinarypractice.com\/wp-json\/wp\/v2\/posts\/1013\/revisions"}],"predecessor-version":[{"id":28070,"href":"https:\/\/navc.sitepreview.app\/todaysveterinarypractice.com\/wp-json\/wp\/v2\/posts\/1013\/revisions\/28070"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/navc.sitepreview.app\/todaysveterinarypractice.com\/wp-json\/wp\/v2\/media\/3049"}],"wp:attachment":[{"href":"https:\/\/navc.sitepreview.app\/todaysveterinarypractice.com\/wp-json\/wp\/v2\/media?parent=1013"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/navc.sitepreview.app\/todaysveterinarypractice.com\/wp-json\/wp\/v2\/categories?post=1013"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/navc.sitepreview.app\/todaysveterinarypractice.com\/wp-json\/wp\/v2\/tags?post=1013"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}